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How Well Do Sunscreens Protect Against Immunosuppression by UV? 
Davenport cl al (p. 859) demonstrate a novel meth od of testing 
sunscreens for protection against immunosuppression b y using 
hUl11an skin explants ill I' itro. Although UV radiation suppresses the 
cutaneo us immune system, the level of immwlOprotection afforded 
by sunscreens is not tested commercially, even though immuno-
suppression resulting from sun exposure may be at least in part 
responsible for the rising incidence of non-melanoma skin can cer 
and melanoma. In order to avoid the difficult problem of trying to 
test for protection from immunosuppression in human subjects, the 
investigators asked whether human skin could be used ill "ilm to 
assess UV -induced immunosuppressio n and protection against im-
munosuppression by sunscreen s. Usin g the mixed epidermal lym-
phocyte reaction as a m easure of skin immune function, the authors 
m easured protection by five sunscreens applied to w hole human 
skin explants that were then exposed to UV irradiation. UV 
radiation of the e"-'Plants produced a UV -dose-dependent decrease 
in epidermal immune function, and all sunscreens tested were full y 
protective aga inst immunosuppression as assessed by this method. 
Further work along this li n e may eventually permit th e routine 
determination of " immune protection facto rs" for Sllllscreen s. 
What Determines the Clinical Features of N eonatal Lupus? 
Miyagawa ef al (p . 881 ) have found a correlation between the 
immunogen etic makeup in anti-Ro/SSA-positive m others and the 
clinical fea tures of neonatal lupus e ryth ematosus (LE). N eonata l LE 
is characterized by two major clinical manifestations, cutaneous 
lupu s and congenital heart block (CHB). There is a tendency fo r 
similar clinical features to occur w ithin a sibship. T his led the 
investigators to look for MHC ChlSS IT associations with the clinical 
featur es of neon atal LE. The authors th ought that it would be 
particularly advantageous to perform such a study in J apan , where 
the population has a relatively homogeneous ethnic background . 
Based on the PCR-RFLP resu lts in 26 J apanese anti-Ro/SSA-
positive mothers with d ifferent neonatal outcom es, the authors 
found a stron g association of a particular m aterna'! I-ILA-DR5 
haplotype with neonatal cutan eous lupus, and other specific hap-
lotypes were associated with CHB. T he fi ndings indicate th at the 
basis for the variation in expression oflupus in neonates may be the 
maternal I-ILA makeup. T his might occur if m aternal HLA poly-
m orphisms are responsibl e fo r va ria tions in anti-Ro/SSA autoim-
mune responses that are in turn de terminin g f.,ctors in th e clinical 
e"-'Pression of LE in neonates. It may be possible wi th thi s in fon11a-
tion to identify mothers at increased l;sk of h aving an affec ted 
infant. 
The Risks of PUV A Are C onfined to the Skin 
Stem et al (p . 897) show that PUV A treatment seem s not to be a risk 
fac tor for non cutaneous malign an t tumors in patients with psoriasis. 
Several previous studies have sugges ted that the risk of some types 
of cancer among persons with psoriasis is il1Creased . PUV A treat-
ment is known to be mutagen.ic and also has immunologic effects 
that might at least in theory increase the ri sk of can cer. T hese 
observations and PUVA's known enhancement of the risk of 
melanoma and squamous cell cancer of the skin led the investiga-
tors to examin e their data from a cohort of PUV A-treated patients 
fo r the occurrence of noncutaneous cancer. By fo llowing this 
cohort for nearly twenty years and comparing the results of the risk 
of visceral cancer with that expected in general population, the 
investigators found that the overall ri sk of noncutan eous cancer in 
the study popul ation did not diffe r fro m the expected rate . For th ree 
sites, thyroid, breast, and cen tral nervous system, out of a tota l ofll 
sites, they noted significant .increases in the incidence of neoplasms, 
but there was n o association be tween cancers at these sites and the 
amount of exposure to PUV A. [n the absence of such an association 
of increased exposure with increased risk, 0 " dose-response rela-
tionship, and because there was a decreasing re lative I;sk with the 
passage of time for aU sites except thyroid , the signifi cance of the 
data on these three sites is limited . These resul ts , w hich span nearly 
two decades of follow-up study, strongly sugges t that lon g- term 
PUVA treatment is not associated w ith an overa ll increased ri sk of 
1l0nCl1 ta neous cancer. 
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Cell-Cell Adhesion in Melanoma 
Matsuyoshi ct al (p. 928) describe new cadherins isolated by PCR 
from human melanoma cells. Melanomas contain nests of cells and 
have the abi]ity to adhere specifically to other melanoma cells, that 
is, to show homophilic cell- cell adhesion, a phenomenon usually 
mediated by ceH-surf.,ce molecules called cadherins. The investi-
gators asked whether melanoma cells express additiona l cadherins 
in addition to E- and P-cadherins, which are expressed by normal 
melanocytes. By testing both types of cells in an aggregation assay, 
the investigators found that melanoma cells, despite their lower 
expression of E- and P-cadherins, have stronger homophilic adhe-
sion activity than do normal epidermalmelanocytes, suggesting that 
melanoma cells may express other cadherins. By PCR with degen-
erate primers, the investigators identified eight kinds of cadherin 
molecules in human melanoma cells, including six novel cadherins. 
The investigators believe that these novel cadherins may be the 
basis for homophilic association of melanoma cells and that changes 
in cadherin expression may be invol ved in the process of malignant 
transformation of melanocytes to melanoma cells. If the novel 
cadherins are found to be specific to melanoma cells, they may be 
useful diagnostic markers and may provide tools for therapy. 
A Cytokine That May Regulate the Hair Growth Cycle 
SchiUi el al (p. 908) have found a possible basis for the control of 
hair growth. It has been recogrlized for over a decade that 
keratinocytes produce parathyroid hormone re lated peptide 
(PTHrP), and PTHrP is also produced in the hair follicle by 
keratinocytes of the inner root sheath. Since PTHrP is known to 
inhibit proliferation and to induce terminal differentiation of kera-
tinocytes, both ill vitro and ill IIillO, the authors asked whether 
PTHrP may have autocrine or paracrine properties in the regulation 
of the hair cycle. If so, PTHrP might cause the hair follicle to 
decrease its proliferative activity and enter the resting phase of the 
hair growth cycle, telogen. Also, the investigators reasoned that if 
they cou ld block the antiproliferative and maturation activity of 
endogenously produced PTHrP by the hair follicle with a PTHrP 
receptor antagonist, it might be possible to still/III ate hair growth, by 
permitting entry into anagen, and possibly to prevent hair follicle 
senescence, the presumed cause of baldness. To try to initiate hair 
follicle proliferative activity, Schilli et al administered PTHrP 
receptor antagonist to mice with hair follicles in the telogen phase. 
To try to prevent or delay hair follicle maturation, they gave the 
receptor antagonist to mice Ul anagen. The receptor antagonist 
stimulated telogen hair follicles to enter into anagen and further-
more delayed the progression of the hair follicles from anagen into 
catagen and telogen. The results raise the possibility that PTHrP 
may be a physiological hair follicle growth control factor respon-
sible for the regulation of the hair cycle. if PTHrP is such a 
modulator, antagonizing PTHrP's action on the hair follicle might 
be a useful strategy for stimulating and maintaining hair growth. 
Alternatively, analogs ofPTHrP with agonist activity might induce 
hair follicle regression and could be usefu l in the treatment of 
hypertrichosis. 
Using Modified Herpes Simplex Virus to Treat Melanoma 
In the past, R andazzo et al have found genetically modified herpes 
simplex virus (HSV) to be effective in the treatment ofCNS tumors 
and mesothelioma Ul animal models. In this issue (p. 933), they 
demonstrate the potential of this approach in the treatment of 
cutaneous melanoma. The authors have enguleered HSV-l mu-
tants that exhibit extremely attenuated replication in normal host 
tissues. causing little damage, but which still demonstrate brisk lytic 
replication in malignant cells. One such mutant, HSV -1716, was 
fowld to infect and kill human melanoma cells efficiently ill Jlitro. 
When injected into subcutaneous melanoma nodules, HSV-171 6 
replicated, but replication was restricted to melanoma nodules, and 
mjection of the eoguleered virus ulto tumors significantly slowed 
tile growth of implanted melanomas. The authors hope that this 
cOlnmon human pathogen, best known for causulg "cold sores," 
may be harnessed as a "molecular scalpel" to selectively destroy 
melanoma. 
